Willemien van den Bos

Prostate Cancer Foundation of Australia

Papers

1

Total Citations

40

H-Index

1

About

Willemien van den Bos is a leading urological researcher whose work centers on advancing minimally invasive treatments for prostate cancer, with a particular focus on focal therapies and their impact on patient quality of life. Her major contributions lie in comparative effectiveness research, most notably through her landmark 2018 study comparing focal irreversible electroporation (IRE) to robot-assisted radical prostatectomy (RARP). This highly cited work (40 citations) provided critical insights into the trade-offs between oncological control and patient-reported quality of life, demonstrating that while both treatments achieve early cancer control, focal IRE offers superior preservation of urinary and sexual function. Van den Bos’s research has been instrumental in shifting the paradigm toward more personalized, less invasive prostate cancer care, challenging the traditional dominance of radical surgery. Her work is widely recognized for its rigorous methodology and patient-centered outcomes, making her a key voice in the ongoing debate about optimal treatment strategies for localized prostate cancer. By pairing clinical outcomes with patient-reported experiences, she has helped bridge the gap between surgical innovation and real-world patient well-being.

Research Focus

Key Achievements

1
H-Index
1
Papers
40
Total Citations
40
Avg Citations/Paper
🏆 Most Cited Paper
Pair-matched patient-reported quality of life and early oncological control following focal irreversible electroporation versus robot-assisted radical prostatectomy
40 citations · 2018
📈 Most Prolific Year: 2018 (1 Papers)
🤝 Key Collaborators: 13
🏛 Institutions: Prostate Cancer Foundation of Australia

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago